1
Scientific article
Real Results of Switching From Adalimumab Original to Adalimumab Biosimilar in Patients With Inflammatory Bowel Disease: The ADA-SWITCH Study
This Spanish multicenter study compares treatment persistence, clinical efficacy, and safety outcomes in patients with inflammatory bowel disease in two patient cohorts: those who maintained the original adalimumab and those who switched to the adalimumab biosimilar. In total, 524 inflammatory bowel disease patients were included in the study. The results indicate that switching to the biosimilar did not impair patient outcomes compared to keeping the original.
Alimentary Pharmacology and Therapeutics
https://onlinelibrary.wiley.com/doi/10.1111/apt.17525
2
ADIEX
Biosimilars Conference: Value-based management
On April 27, the Valencian Society of Hospital Pharmacy, in collaboration with Pfizer, held the conference "Biosimilars: Value-based management" in Valencia. The main challenges of managing biosimilar medicines were addressed. It was also possible to discuss their contribution to the sustainability of the SNS from the perspective of all the agents involved in its management and management (the health administration, the hospital pharmacy and clinical specialists), in addition to the future challenges that are yet to come.
Valencian Society of Hospital Pharmacy
https://www.youtube.com/watch?v=0wsTK-r51LA&t=16s
3
Article
Exchange of biosimilar medicines: effective, safe and efficient
In this monographic bulletin on the exchange of biosimilar medicines, the Government of Navarra does an extensive sweep of the panorama of biosimilars, from general questions about the approval of these drugs to data on use by active ingredient and its evolution in the foral community. Regarding its title, it is based on the declaration of the EMA and the HMA in September 2022 on the interchangeability of biosimilar medicines. Noteworthy is Annex 2, which shows the question and answer sheet also prepared by the Government of Navarra to resolve the frequent doubts of professionals and patients about these drugs.
Navarre pharmacotherapeutic information bulletin
4
Scientific article
Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021
This study shows that the use of biosimilars in the area of oncology (bevacizumab, epoetin alfa, filgrastim, pegfilgrastim, rituximab and trastuzumab) meant that the average cost per dose decreased between 2019% and 2021%, depending on the period 24-41. of the active principle. It is based on data from PracticeNET (which includes practice data and opinions from prescribers and practice leaders to reveal potential drivers and barriers to the use of biosimilars). Notably, compared to private health plans, Medicaid plans and traditional Medicare showed lower acceptance of biosimilar drugs, leaving additional opportunity for increases in biosimilar use among certain practices and payers.
JCO Oncology Practice
https://pubmed.ncbi.nlm.nih.gov/37084324/
5
Report
Annual report. Contribution of the European Medicines Agency to science, medicines and health in 2022
This report provides an overview of the Agency's activities to protect and promote public and animal health in the European Union. It highlights that the key events of the year 2022 presented in a timeline include the joint statement HMA - EMA on the interchangeability of biosimilar medicines. On page 66 of the report, highlighted in yellow, you can see the biosimilar medicines evaluated by the EMA in 2022, a total of 8 corresponding medicines from the therapeutic areas of endocrinology, ophthalmology, oncology and hematology.